Mexiprim, 50 mg/ml 2 ml 10 pcs

Mexiprim belongs to the heteroaromatic antioxidants.

It has a wide range of pharmacological activity: increases the body’s resistance to stress, shows anxiolytic effect, not accompanied by drowsiness and myorelaxant effect; has nootropic properties, prevents and reduces learning and memory disorders arising from aging and exposure to various pathogenic factors; has anticonvulsant effect; shows antioxidant and antihypoxic properties; increases attention concentration and performance; weakens the toxic effects of alcohol.

The drug improves brain tissue metabolism and blood supply, improves microcirculation and blood rheology, reduces platelet aggregation.

Stabilizes membrane structures of blood cells (erythrocytes and platelets). It has hypolipidemic effect, decreases the total cholesterol and low-density lipoproteins.

The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective effect.

It inhibits lipid peroxidation, increases superoxidase activity, increases lipid-protein ratio, decreases membrane viscosity and increases its fluidity.

Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine) that increases their ability to bind to ligands, maintains structural and functional organization of biomembranes, neurotransport and improves synaptic transmission.

Mexiprim increases dopamine content in the brain.

Causes compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle in hypoxia with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Pharmacokinetics

Maximum concentration of Mexiprim in plasma is within the range of 50 to 100 ng/ml.

Half-life of Mexiprim and average time of drug retention in the body are 4.7-5.0 hours and 4.9-5.2 hours respectively.

Mexiprim in humans is extensively metabolized to form its glucuron-conjugated product.

On average over 12 hours 0.3% of unchanged drug and 50% as glucuronoconjugate of the administered dose are excreted with urine.

Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after drug administration.

Indicators of urinary excretion of Mexiprim and its conjugated metabolite have significant individual variability.

Indications

Attention and memory disorders, Dizziness, Headache, Stenocardia, Weakness and fatigue, Anxiety

• Acute cerebral circulation disorders (as part of complex therapy);
• Dyscirculatory encephalopathy;
• Vegevascular dystonia;
• Anxiety in neurotic and neurosis-like conditions;
• .Mild cognitive disorders of different genesis (psychoorganic and asthenic syndromes, craniocerebral trauma, atherosclerosis, senile and atrophic processes, neuroinfections and intoxications);
• Memory disorders and mental retardation in elderly people;
• Exposure to extreme (stressful) factors;
• Abstinent syndrome in alcoholism with a predominance of neurosis-like and autonomic-vascular disorders;
• Acute intoxication with antipsychotic medications.

.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Composition per 1 ml:

Ethylmethylhydroxypyridine succinate – 50 mg

Water for injection – up to 1 ml.

How to take, the dosage

Mexiprim is administered intramuscularly or intravenously (by trickle or drip). Doses are adjusted individually.

During infusion method the drug should be diluted in physiological sodium chloride solution.

The treatment begins with a dose of 50-100 mg 1 to 3 times a day and the dose is gradually increased until therapeutic effect is achieved.

Mexiprim is slowly administered by jetting for 5-7 minutes, by drip – at the rate of 40-60 drops per minute. The maximum daily dose is not more than 800 mg.

In acute disturbances of cerebral circulation Mexiprim is used in combination therapy in the first 2-4 days by intravenous drip by 200-300 mg once a day and then intramuscularly by 100 mg three times a day. The therapy period is 10-14 days.

In patients with dyscirculatory encephalopathy in the decompensation phase Mexiprim should be administered intravenously by trickle or dropwise in the dosage of 100 mg 2-3 times a day during 14 days.

Then the drug is administered intramuscularly in doses of 100 mg 2-3 times a day during the next two weeks. For course prophylaxis of discirculatory encephalopathy the preparation is administered intramuscularly in dose of 100 mg 2 times a day during 10-14 days.

In case of light cognitive disorders in elderly patients and in case of anxiety disorders the preparation is administered intramuscularly in daily dose 100-300 mg daily during 14-30 days.

In case of withdrawal alcohol syndrome Mexiprim is administered in dose of 100-200 mg intramuscularly 2-3 times a day or intravenously dropwise 1-2 times a day during 5-7 days.

In acute intoxication with antipsychotic agents the drug is administered intravenously in dose 50-300 mg daily during 7-14 days.

Interaction

Mexiprim is compatible with psychotropic drugs; increases the effect of benzodiazepine anxiolytics, antiparkinsonian drugs and carbamazepine.

Reduces the toxic effects of ethyl alcohol.

Special Instructions

During treatment, caution should be exercised when driving motor vehicles and engaging in other potentially dangerous activities that require high concentration and rapid psychomotor reactions.

Contraindications

Acute hepatic and/or renal failure, hypersensitivity to the drug.

Childhood age, pregnancy, breast-feeding – due to the insufficient study of the drug action in these categories of patients.

Side effects

Rarely – nausea, dry mouth, drowsiness, allergic reactions.

Overdose

Symptoms: insomnia (insomnia, in some cases – drowsiness).

Treatment: usually does not require – symptoms disappear on their own within 24 hours.

In severe cases of insomnia is recommended to take sleeping pills.

Similarities

Mexidol, Mexifin, Neurox, Medomexi, Mexicor, Evrin, MetucinVel, Neuromexol